Videos
The SCIEX 7500+ system offers ultrasensitive quantitation, rigorously tested on challenging matrices. It ensures reliable detection of low-level compounds in complex samples while minimizing downtime. Featuring: Rathna Veeramachaneni, Ph.D. Interested in speaking with one of our experts? Fill out the form below to connect with…
Blogs
Accurately quantifying cisplatin in human plasma by LC-MS/MS can be challenging due to matrix effects caused by endogenous plasma components, particularly in hemolyzed samples. At WRIB 2025, scientists from KCAS Bio and Lilly presented a novel bioanalytical approach designed to…
Blogs
Oligonucleotide therapeutics continue to reshape drug development by targeting disease pathways at the genetic level. Antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and antibody-RNA conjugates (ARCs) are expanding the range of treatable diseases, particularly for targets that were previously considered inaccessible to conventional therapeutics. As these modalities evolve,…
Blogs
In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in…
Posters & Papers
Discover in this poster presented by Taylor Dufield at WRIB 2026 about a fit-for-purpose multiplex LC–MS/MS workflow combining online and offline anti-peptide immunoprecipitation that enables sensitive, selective quantitation of protein biomarkers and binding partners from a single digested tissue sample across multiple species using a validated ICH M10-aligned approach.
Posters & Papers
Discover in this poster presented by Ryan Darling at WRIB 2026 on how a validated hybrid immunoaffinity LC–MS/MS method using a surrogate peptide and 2D chromatography enables selective, sub-ng/mL quantitation of a KLK1 analog in human plasma, overcoming LBA limitations caused by near-identical endogenous KLK1. If you have…
Posters & Papers
This presentation, given at the 2025 AAPS PharmSci Conference by Dawn Dufield, PhD, Scientific Officer of Mass Spectrometry at KCAS Bio, reviews Bioanalytical Strategies for Therapeutic Drugs and Their Conjugates (ADCs, Oligos, siRNA, ASOs and AOCs/ARCs) by QqQ/HRMS. If you have any questions about these services or any…
Blogs
What is Hybrid LC-MS/MS Hybrid LC-MS/MS is a technique that combines an affinity capture step with LC-MS/MS detection. It typically requires only one antibody, in contrast to conventional ligand-binding assays (LBAs), which usually need two. This approach leverages the combined selectivity of affinity extraction and the…
Posters & Papers
Discover in this poster presented by Ryan Darling at the AAPS National Biotechnology Conference 2025 on the use of a hybrid LC-MS/MS approach for the quantitation of total antibody TAb and intact Antibody Drug Conjugate (ADC). If you have any questions about these services or any…
Blogs
ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to…
Blogs
Antibody-drug conjugates (ADCs) have been conventionally developed for a wide range of oncological applications since the first ADC approval in 2000 by the FDA. Typically, an ADC consists of three main components: antibody, linker conjugate, and therapeutic drug (payload). The mechanism of an ADC involves the antibody binding to a…
webinars
As the pharmaceutical industry continues to evolve, so does the technology behind drug development. One of the most groundbreaking advancements in bioanalysis is Hybrid LC-MS/MS technology, which is rapidly becoming the new standard for analyzing Antibody Drug Conjugates (ADCs). KCAS Bio is proud to be at the forefront of…